Nutex Health Past Earnings Performance

Past criteria checks 0/6

Nutex Health's earnings have been declining at an average annual rate of -54.7%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been declining at an average rate of 16.7% per year.

Key information

-54.7%

Earnings growth rate

-96.9%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate-16.7%
Return on equity-54.9%
Net Margin-18.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?

Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?

Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks

Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks

Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target

Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target

Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues

Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues

Nutex Health GAAP EPS of -$0.03, revenue of $58.05M

Aug 23

Revenue & Expenses Breakdown
Beta

How Nutex Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NUTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23248-46360
30 Sep 23232-29370
30 Jun 23197-436360
31 Mar 23196-451300
31 Dec 22219-425200
30 Sep 22229-396190
30 Jun 2231970170
31 Mar 22336122160
31 Dec 2133213350
30 Sep 21374159250
31 Dec 20274106100
31 Dec 199721200

Quality Earnings: NUTX is currently unprofitable.

Growing Profit Margin: NUTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NUTX is unprofitable, and losses have increased over the past 5 years at a rate of 54.7% per year.

Accelerating Growth: Unable to compare NUTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUTX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.1%).


Return on Equity

High ROE: NUTX has a negative Return on Equity (-54.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.